Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
32.31M | 78.12M | 19.71M | 25.54M | 90.73M | Gross Profit |
32.31M | -99.53M | 13.38M | 20.49M | -67.26M | EBIT |
-251.15M | -169.18M | -225.95M | -193.15M | -134.84M | EBITDA |
-233.11M | -163.12M | -219.61M | -188.09M | -130.88M | Net Income Common Stockholders |
-237.09M | -153.22M | -204.35M | -185.11M | -109.41M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
269.91M | 323.11M | 437.37M | 619.91M | 511.77M | Total Assets |
341.59M | 499.15M | 514.32M | 677.48M | 572.60M | Total Debt |
35.03M | 36.54M | 43.95M | 26.38M | 26.14M | Net Debt |
-96.51M | -87.12M | -97.58M | -177.14M | -113.55M | Total Liabilities |
207.31M | 150.06M | 153.64M | 123.84M | 179.02M | Stockholders Equity |
134.27M | 349.10M | 360.68M | 553.64M | 393.59M |
Cash Flow | Free Cash Flow | |||
-219.11M | -136.90M | -181.47M | -171.78M | -187.00M | Operating Cash Flow |
-210.28M | -132.18M | -177.35M | -163.80M | -179.84M | Investing Cash Flow |
162.15M | -3.73M | 114.07M | -54.47M | -140.52M | Financing Cash Flow |
56.03M | 118.04M | 1.28M | 282.11M | 224.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
52 Neutral | $152.36M | ― | -140.82% | ― | -48.37% | -44.70% | |
49 Neutral | $110.12M | ― | -58.55% | ― | 825.97% | 38.32% | |
39 Underperform | $125.59M | ― | -26.10% | ― | ― | 30.76% | |
39 Underperform | $130.70M | ― | -75.60% | ― | ― | -2.29% | |
39 Underperform | $122.63M | ― | -91.32% | ― | -100.00% | -244.85% | |
33 Underperform | $120.19M | ― | -79.05% | ― | ― | -0.42% |
At the 2025 Annual Meeting of Stockholders held on May 29, Editas Medicine, Inc.’s stockholders approved significant amendments to the company’s 2015 Stock Incentive Plan, extending its term and eliminating the ‘evergreen’ provision, among other changes. Additionally, stockholders approved an increase in the number of authorized shares of the company’s capital stock, which could impact the company’s ability to raise capital and expand its operations.
The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
On May 14, 2025, Editas Medicine announced new in vivo data showcasing the potential of their gene upregulation strategy in hematopoietic stem cells (HSCs) at the American Society of Gene and Cell Therapy Annual Meeting. The data demonstrated that a single dose of their proprietary targeted lipid nanoparticle (tLNP) achieved therapeutically relevant levels of HBG1/2 promoter editing in both humanized mice and non-human primates, exceeding the predicted therapeutic threshold. This approach, which targets HBG1/2 promoters to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia, potentially positioning Editas Medicine as a leader in in vivo gene editing therapies.
The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
On May 13, 2025, Editas Medicine announced in vivo proof of concept data for a liver target at the American Society of Gene and Cell Therapy Annual Meeting. The study demonstrated significant gene editing and protein upregulation in mice and monkeys, indicating potential for a first-in-class treatment for liver diseases. This advancement positions Editas as a leader in gene editing therapies, with plans to reveal more details about the target and development candidate later in the year.
The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
On March 18, 2025, Editas Medicine announced the resignation of Erick Lucera, its Executive Vice President and Chief Financial Officer, effective March 28, 2025. Amy Parison, who has been with the company since January 2025, will succeed him, bringing extensive experience from her previous roles at Rubius Therapeutics and Vertex Pharmaceuticals. The transition includes new compensation terms for Ms. Parison, highlighting her strategic importance to the company.